Novo Nordisk A/S slumped after a pill from rival Eli Lilly & Co. helped patients shed weight and control blood sugar about as ...

Times are changing, and unpredictability has become the new normal when it comes to tariffs and world trade. Nobody outside ...

The scale of President Donald Trump’s tariffs has exceeded even the most bearish forecasts — and could impact these five ...

The global capability centre of Novo Nordisk in India is now closely engaged with the entire value chain of this global ...

The Startup Policy Forum (SPF)—which represents over 50 tech firms—said it has urged the Indian government to create a ...

Novo Nordisk A/S has moved -53.6% over the last year, and the S&P 500 logged a change of 5.4% NVO has an average analyst ...

Eli Lilly's robust sales for Mounjaro and Zepbound along with its positive outlook for 2025 also work in its favor. Click ...

The global pharmaceutical industry could generate about $1.2 trillion in sales in 2025, according to Statista, and projections call for 4.7% annual growth through 2029. The cancer treatment segment ...

A spokesperson confirmed the Danish drugmaker has asked U.S. regulators to clear an oral version of its weight loss drug ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Novo Nordisk (NYSE:NVO) stock has experienced a significant decline, dropping 35% from over $90 in early March to around $58 ...

Eli Lilly and Novo Nordisk dominate the billion-dollar weight loss drug market. Lilly has announced positive trial results ...